Trial Search Results

Platelet Rich Plasma for Patients With Recurrent Implantation Failure

Patients with recurrent implantation failure are among the most difficult patients to treat, with no proven standard treatment. Platelet rich plasma stimulates cellular processes involved in endometrial regeneration, and in a small case series has shown efficacy for this patient population. We hope to conduct a randomized controlled pilot study to determine whether PRP is indeed an effective treatment for recurrent implantation failure.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Combination Product: Platelet rich plasma
  • Combination Product: Placebo


Early Phase 1


Inclusion Criteria:

   - All women who have undergone 3 or more embryo (blastocyst stage) transfers without
   establishing a clinical pregnancy or 2 or more euploid embryo transfers without
   establishing a clinical pregnancy, aged 18 - 45, with a normal uterine cavity
   established within 12 months by hysteroscopy or saline infusion sonogram, planning in
   vitro fertilization with an embryo transfer at Stanford Fertility and Reproductive
   Health. The planned transfer must consist of any of the following: a PGS proven
   euploid embryo, a good quality blastocyst from a patient younger than 37, or a donor
   oocyte blastocyst.

Exclusion Criteria:

   - Abnormal uterine cavity, planning in vitro fertilization with use of a gestational
   carrier. patients enrolled in other experimental interventions for RIF will be
   excluded. Patients with only poor quality or cleavage stage embryos.

Ages Eligible for Study

18 Years - 45 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jonathan D Kort, M.D.